us for to you joining Thanks, everyone thank Jason, and today.
just frame accelerating look We strengthening on our transformation. talk our in strategic profitable to elevating quarter, about I are an of and want our pillars like growth what's making the And three pleased to provide business. growth foundation, OraSure's I the on our core update before progress the
and restructuring improved rebalancing flow organizational generation. our balance our has sheet and cash is that Strengthening cost
expand our segments and capabilities and product strategic and internally in on these partnerships the market we is leveraging serve. strengths our focus to portfolio Elevating core the
segments end while mid- rebuild for and investing our about long-term profitable is momentum. Accelerating growth
A QX core first our quarter include, few delivered for the both and notable revenue products. we exceeded that ranges revenue COVID-XX highlights during guidance
foundation As facilities, to including known and streamline strengthening on focus our our activities operational services Bethlehem Novosanis analytical other our microbiome taking consolidating our operations, into part enterprise-wide sequencing in-sourcing, of laboratory as Diversigen, and locations. efficiency, third-party into next exiting are we manufacturing steps in our our site and Belgium business
around expected result over to These and cost the are significant end and structure our operating cash rightsize to are savings from and our business years achieve initiatives our align core XXXX. by next breakeven cost our in important flow steps the X strength to target of
are Diagnostics start. our announced partnerships to Next, earlier we strong and this strategic with year off that Sapphiros Direct a
investing Starting with in growth. position existing our healthy to our innovation leverage road we efficiency. in order balance And to strength partnerships operating with our sheet, and profitable for OTI map are
We continue to our strengthen foundation.
As we've in tremendous efficiency made we enterprise-wide operating mindset an delivers discussed over the streamlining progress have footprint improving last establishing our XX improvement. that and continuous months, our
rebalance steps efforts, and for cost structure OTI these part As success. are of position additional long-term to we taking our
Diversigen CoreBiome down services of quarter. Diversigen the based acquired OTI wind in by to steps the sequencing market. and potential initiated the we First, microbiome the on end of XXXX third
to microbiome segment. COVID-XX segment, impacted in while factors and negatively external meaningful the lacking in experienced have growth pandemic revenue a success, other line this services near-term early Despite we market the decline and sight have of
business. business our and strengths, limited scaling profitably microbiome sequencing prioritization to other visibility services have the decided our exit to the core we Given of
the systems participate we kits sample our and distribution our management will providing Anaerobe continue in continuity clients We microbiome and to serve focused segment leader a to transitioning on Plus, for it's important of our them in DNA space. and to with are the Genotek collection offerings. note,
of In-sourcing production in sample activities XX infrastructure. in-source Canada months. commenced external certain our Pennsylvania existing next is efficiency of into Bethlehem, center products we excellence the manufacturers projects from and these our capabilities our over management further leverage to in expected manufacturing contract Second, improve and operating to
planning Belgium by our in exit the integrate year Novosanis existing into this Third, we our end activities are site infrastructure. to and of those
to Colli-Pee will and management continue We develop collection device part sample the solutions. of sell as urine our
$XX to operating they business result by total, flow in are these the are from cash completion achieving reductions our and of important actions of targets incremental In steps expected million following breakeven to in more expense annual in core end XXXX. than our
of to in revenue million QX. InteliSwab Moving generated COVID-XX. $XX
visibility our largest have during quarter, expected the remaining we contract U.S. with are to that discussed QX. fulfill we the As InteliSwab to order trends of last portion government
COVID-related Moving to was our core $XX core the of high QX which products. range. at excludes million guidance of business, revenue our end
period Program, diagnostics Home molecular in Performance the core our HIV in at-home for Take Within Together both guidance. consistent test business, core management embedded March markets or outlook that XX-month with kit and XXXX sample Me wrapped the up Diagnostics the distribution. includes initial our
you test As the all remember, public across Me in Puerto states XX goal kits private with collaborative in a and the provide is to Rico. effort Take Together may sector, Home free HIV
plans Initial X the test deployed. tests kits were year distribute X-year of for per million program a XXX,XXX to during total
HIV reported expectations. program, people tested who has to However, XX% far collected never the According the data had test of they demand for before. orders for were by exceeded
program stigma empowers services. testing care The reducing access demonstrates success HIV and about impact individuals barriers to to and their positively prevention combat how health, care learn to
play role important this year. We in are proud and a look to to program forward second a successful
under expand emerges the industry portfolio market can allow molecular provide amongst that management partnerships our post-COVID sales and sets us sample direct existing syphilis for and to for orders diagnostic we our call, preserve, successfully environment. of first how products enter health capabilities.
Shifting environment and previously. we test Anaerobe others. System, leverage we new care announced biome Since as our solutions. delivered We market segments of to the muted our the launches demonstrate partnerships customers comprehensive distribution last to remains These The the launched
factors and working organizations we our our for related sciences remain a In research addition with environments uncertainty leadership short-term structures.
Even solutions evolving customers uncertainty for opportunities the to diagnostic funding for near-term in confident however, as and to longer-term while continue and these management sample reinforce mid- regulatory headwinds, few and academic labs, such priorities market corporate life through to we position.
of we sample As end recover, of begin our a to industry-leading reasons. segments provider position as solutions our confident an are number management for in
with LDTs. consistency demonstrate complex management record regulatory track including approval continue navigating the partners and successfully diagnostic to we Also, quality collection in contemplate categories. important collaborating will XXX(k) We our even FDA processes more as several cleared our solutions, regulation of devices our and believe stabilization sample become of labs and for our of they
developed strong of a And reliability very result we sales consistent customer as execution, our and our relationships have team. experienced
clinical onboarding research We segments, as customers by across including companies, continue to global position well leadership as labs, as well new our multiple reference biopharma reinforce nonhuman segments.
they represent of work offering as and the revenue a growth from today, percentage small future represent orders they're opportunities progresses. While customers discovery our these scale their
empower provides that new genetic multiyear Oragene the XXX(k) action innovators note, services. and relationships are In customers, this with device provide individuals space. to are the tools testing to long-standing genetic to a to to to in proud deal hold we health. continue we on health we've them On pioneers insights and share in pleased and used addition be to collection with their their signed recently FDA-cleared our to take XXandMe XXandMe with ancestry onboarding
acquisitions. growth. includes From evaluate investments and an This that innovation accelerate strategic can make potential potential standpoint, both our investments our inorganic continue through and in to we opportunities product and pipeline partnerships internal
balance and scale positive we our and continue strong opportunities the business. be differentiators and current important accelerate for our to to environment as profitably market flow sheet Our in generation cash growth economic look
serve. highlights sustainability I'd for Relations our employees, Before ESG initiatives are governance-related our stakeholders on efforts published recently create I we OraSure to like value and customers, external to internal global conclude, XXXX that This XXXX, to website. we progress in advancing to our that communities shareholders and our Investor our that the and report meaningful our highlight and Cares, report
our over I'd to to guidance. to financial that, turn results our like With Ken and call discuss
